Company intelligence / Profile preview

FTG

Ownership: Private
Development stage: Commercial

Overview

FTG is a discovery and early development biotech company focused on innovative therapeutics, with its lead program being a small molecule mTOR inhibitor currently in preclinical development for cancer and rare diseases. No clinical results have been reported yet.

Therapeutic areas: OncologyRare Diseases
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on FTG.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FTG.

Explore the full profile